<?xml version="1.0" encoding="UTF-8"?>
<p>Another interesting antimalarial quinine with anti-ZIKV activity is amodiaquine (AQ). A high-content screening study identified its ability to prevent ZIKV infection and its toxicity in human pluripotent stem cell-derived neural progenitors [
 <xref rid="B80-pharmaceuticals-12-00060" ref-type="bibr">80</xref>]. Moreover, it showed comparable results to CQ when tested against Asian PLCal_ZV ZIKV strain in Vero cells [
 <xref rid="B81-pharmaceuticals-12-00060" ref-type="bibr">81</xref>]. In an adult immunodeficient mouse model, seven days of treatment with AQ (40 mg/kg/day s.c.) led to lower ZIKV RNA levels and decreased levels of ZIKV E-protein in the brain [
 <xref rid="B80-pharmaceuticals-12-00060" ref-type="bibr">80</xref>]. Three AQ derivatives, quinacrine, mefloquine, and GSK369796, were also able to inhibit viral replication with an EC
 <sub>50</sub> within the micromolar range, indicating that AQ is also an interesting scaffold molecule for drug development (Balasubramanian, 2017). AQ has been used for treatment of malaria in pediatric settings, but serious adverse effects were shown after its long-term use for prophylaxis [
 <xref rid="B130-pharmaceuticals-12-00060" ref-type="bibr">130</xref>]. Therefore, studies should focus on its development as short-term prophylactic drug or post-exposure treatment.
</p>
